APOE Genotype Effects on Alzheimer's Disease Onset and Epidemiology
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Blessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117 · cited 1×
“The pathophysiology of AD has been studied extensively in the last three decades, since the watershed studies of Blessed et al. (1968) began to clarify the relationship of AD dementia to senile plaques Journal of Molecular Neuroscience Volume 23, 2004 (SPs) and neurofibrillary tangles (NFTs).”
BackgroundAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
CNS synaptogenesis promoted by glia-derived cholesterol
Mauch, D. H., Nägler, K., Schumacher, S., Göritz, C., Müller, E.-C., Otto, A., & Pfrieger, F. W. (2001) · Science · doi:10.1126/science.294.5545.1354 · Cited by 1,711
APOLIPOPROTEIN E ALLELES AS RISK FACTORS IN ALZHEIMER'S DISEASE
Roses, M. D. (1996) · Annual Review of Medicine · doi:10.1146/annurev.med.47.1.387 · Cited by 707
Modern human origins: progress and prospects
Stringer, C. (2002) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.2001.1057 · Cited by 534 · cited 2×
“The recent theory derived from mitochondrial DNA, that there are three African lines extending back 180,000 yr (Oppenheimer, 2003; Stringer, 2002), whereas non- African lines appear to have branched off about 80,000 yr ago, suggests that there might be numerous other genetic factors involved in AD…”
BackgroundGrowth processes in teeth distinguish modern humans from Homo erectus and earlier hominins
Dean, C., Leakey, M. G., Reid, D., Schrenk, F., Schwartz, G. T., Stringer, C., & Walker, A. (2001) · Nature · doi:10.1038/414628a · Cited by 517 · cited 1×
“There is evidence that growth of tooth enamel changed at that time, distinguishing modern humans from earlier hominids (Dean et al., 2001).”
BackgroundApoE-4 and Age at Onset of Alzheimer's Disease: The NIMH Genetics Initiative
Blacker, D., Haines, J. L., Rodes, L., Terwedow, H., Go, R. C. P., Harrell, L. E., Perry, R. T., Bassett, S. S., Chase, G., Meyers, D., et al. (1997) · Neurology · doi:10.1212/wnl.48.1.139 · Cited by 479 · cited 1×
“The APOE ε4 allele confers its maximal effect on risk before age 70 (Blacker et al., 1997), partly explaining why some studies looking at older populations have not found the full effect of this allele.”
Background
Cited by
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Molecular mechanisms of neurodegeneration in Alzheimer's disease
Crews, L., & Masliah, E. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq160 · Cited by 772
Alzheimer's disease as homeostatic responses to age-related myelin breakdown
Bartzokis, G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.08.007 · Cited by 546
“Membrane cholesterol and LOAD genes: ApoE nd low-density lipoprotein receptors (LDLr) After age itself, ApoE is the second most important risk actor for LOAD and by far its single most important genetic actor (Ashford, 2004; Raber et al., 2004).”
Lipids and Alzheimer’s Disease
Kao, Y.-C., Ho, P.-C., Tu, Y.-K., Jou, I.-M., & Tsai, K.-J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041505 · Cited by 485
ApoE4: an emerging therapeutic target for Alzheimer’s disease
Safieh, M., Korczyn, A. D., & Michaelson, D. M. (2019) · BMC Medicine · doi:10.1186/s12916-019-1299-4 · Cited by 449
Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease
Whiley, L., Sen, A., Heaton, J., Proitsi, P., García-Gómez, D., Leung, R., Smith, N., Thambisetty, M., Kloszewska, I., Mecocci, P., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.001 · Cited by 340
Neurogenesis and Alzheimer's disease: At the crossroads
Lazarov, O., & Marr, R. A. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.08.009 · Cited by 327
Metabolic Dysfunction in Alzheimers Disease and Related Neurodegenerative Disorders
Cai, H., Cong, W.-N., Ji, S., Rothman, S., Maudsley, S., & Martin, B. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015064 · Cited by 306
The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE
Guerreiro, R. J., Gustafson, D. R., & Hardy, J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.025 · Cited by 285
“This allele represents an increased risk seen across different ethnic groups of 3-fold for heterozygous carriers and up to 15-fold for individuals who are 4 homozygotes, when compared with 3 homozygotes (Ashford, 2004).”
Bakulski, K. M., Dolinoy, D. C., Sartor, M. A., Paulson, H. L., Konen, J. R., Lieberman, A. P., Albin, R. L., Hu, H., & Rozek, L. S. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111223 · Cited by 255
“Approximately 60% of LOAD cases carry at least one apolipoprotein 4 allele (APOE- 4), while the global population prevalence of the allele is only approximately 22% [5, 6].”
Ritchie, K., Carriere, I., Ritchie, C. W., Berr, C., Artero, S., & Ancelin, M.-L. (2010) · BMJ · doi:10.1136/bmj.c3885 · Cited by 250
Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease
Drzezga, A., Grimmer, T., Henriksen, G., Mühlau, M., Perneczky, R., Miederer, I., Praus, C., Sorg, C., Wohlschläger, A., Riemenschneider, M., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a2e8d0 · Cited by 248
Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease
Vemuri, P., Wiste, H. J., Weigand, S. D., Knopman, D. S., Shaw, L. M., Trojanowski, J. Q., Aisen, P. S., Weiner, M., Petersen, R. C., Jack, C. R., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21953 · Cited by 195
“Age of clinical AD onset is lowered by 5 to 10 years in ε4 carriers relative to noncarriers.(1,51,52) This is supported in our data by the fact that among both AD and aMCI subjects ε4 carriers are younger than noncarriers; that is, carriers reach the same clinical disease stage at a younger age.”
Herpes Viruses Increase the Risk of Alzheimer’s Disease: A Meta-Analysis
Steel, A. J., & Eslick, G. D. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-140822 · Cited by 154
APOE Genotype and Neuroimaging Markers of Alzheimer’s Disease: Systematic Review and Meta-Analysis
Liu, Y., Yu, J.-T., Wang, H.-F., Han, P.-R., Tan, C.-C., Wang, C., Meng, X.-F., Risacher, S. L., Saykin, A. J., & Tan, L. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307719 · Cited by 152
APOE genotype and early β-amyloid accumulation in older adults without dementia
Lim, Y. Y., Mormino, E. C., Initiative, F. T. A. D. N., Initiative, A. D. N., Weiner, M., Aisen, P., Weiner, M., Aisen, P., Petersen, R., Jack, C. R., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004336 · Cited by 125
“The APOE e2 allele is a strong protective genetic factor against AD dementia.(11,26) Our results suggest that this protection is at least in part mediated by slower rates of Ab accumulation.”
BackgroundGenetic Determinants of Human Health Span and Life Span: Progress and New Opportunities
Martin, G. M., Bergman, A., & Barzilai, N. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030125 · Cited by 120
“exception of the important risk factor of the epsilon 4 allele at the APOE locus (reviewed by [49]), numerous candidate loci remain to be fully validated as contributors to the much more common late onset forms of late-life dementia.”
BackgroundBartzokis, G., Lu, P. H., Geschwind, D. H., Tingus, K., Huang, D., Mendez, M. F., Edwards, N., & Mintz, J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.024 · Cited by 109
On the origin of proteins in human drusen: The meet, greet and stick hypothesis
Bergen, A. A., Arya, S., Koster, C., Pilgrim, M. G., Wiatrek-Moumoulidis, D., van der Spek, P. J., Hauck, S. M., Boon, C. J. F., Emri, E., Stewart, A. J., et al. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.12.003 · Cited by 101
Luck, T., Riedel-Heller, S. G., Luppa, M., Wiese, B., Köhler, M., Jessen, F., Bickel, H., Weyerer, S., Pentzek, M., König, H.-H., et al. (2014) · Psychological Medicine · doi:10.1017/s0033291713001918 · Cited by 93
“The ε4 allele of apolipoprotein E (APOE) is the most important currently known genetic risk factor for lateonset Alzheimer’s disease (AD) dementia (Paulson & Igo, 2011), and is thought to account for around 20–50% of the attributable total risk for dementia (Slooter et al. 1998; Ashford, 2004).”
BackgroundUsing genetics to enable studies on the prevention of Alzheimer's disease
Crenshaw, D. G., Gottschalk, W. K., Lutz, M. W., Grossman, I., Saunders, A. M., Burke, J. R., Welsh-Bohmer, K. A., Brannan, S. K., Burns, D. K., & Roses, A. D. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.222 · Cited by 70
Baker-Nigh, A. T., Mawuenyega, K. G., Bollinger, J. G., Ovod, V., Kasten, T., Franklin, E. E., Liao, F., Jiang, H., Holtzman, D., Cairns, N. J., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.721779 · Cited by 54
“Taken together, variations in the APOE gene may account for at least 50% of the population-attributable risk in late-onset AD (5).”
BackgroundFan, Y.-Y., Cai, Q.-L., Gao, Z.-Y., Lin, X., Huang, Q., Tang, W., & Liu, J.-H. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.04.017 · Cited by 49
Effect of Carboxyl-Terminal Truncation on Structure and Lipid Interaction of Human Apolipoprotein E4
Tanaka, M., Vedhachalam, C., Sakamoto, T., Dhanasekaran, P., Phillips, M. C., Lund-Katz, S., & Saito, H. (2006) · Biochemistry · doi:10.1021/bi060023b · Cited by 43
Role of Microglia in Regulating Cholesterol and Tau Pathology in Alzheimer’s Disease
Nanjundaiah, S., Chidambaram, H., Chandrashekar, M., & Chinnathambi, S. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00883-6 · Cited by 36
Langella, S., Barksdale, N. G., Vasquez, D., Aguillon, D., Chen, Y., Su, Y., Acosta-Baena, N., Acosta-Uribe, J., Baena, A. Y., Garcia-Ospina, G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40775-z · Cited by 30
Walsh, T., Duff, L., Riviere, M. E., Tariot, P. N., Doak, K., Smith, M., Borowsky, B., Lopez Lopez, C., Arratia, P. C., Liu, F., et al. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.27 · Cited by 18
“Here we describe the tactics and strategies and their success in the outreach, recruitment, screening, and enrollment of participants into the API Generation Program, with a specific focus on identifying and enrolling cognitively unimpaired APOE ε4 HMs given the 2-3% prevalence of this genotype in the population (16,…”
MethodGeroldi, D., Minoretti, P., Bianchi, M., Di Vito, C., Reino, M., Bertona, M., & Emanuele, E. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.06.014 · Cited by 18
Metadata
- Authors
- Ashford, J. W.
- Venue
- Journal of Molecular Neuroscience
- Published
- 2004
- Volume
- 23
- Issue
- 3
- Pages
- 157-166
- ISSN
- 0895-8696 (ISSN-L)
- OpenAlex
- W2109666614
- Cited by
- 235
- References
- 17
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.